296 related articles for article (PubMed ID: 35757327)
21. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
[TBL] [Abstract][Full Text] [Related]
22. Anthracycline-induced cardiotoxicity and renin-angiotensin-aldosterone system-from molecular mechanisms to therapeutic applications.
Sobczuk P; Czerwińska M; Kleibert M; Cudnoch-Jędrzejewska A
Heart Fail Rev; 2022 Jan; 27(1):295-319. PubMed ID: 32472524
[TBL] [Abstract][Full Text] [Related]
23. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
[TBL] [Abstract][Full Text] [Related]
24. Anthracycline cardiotoxicity after breast cancer treatment.
Hershman DL; Shao T
Oncology (Williston Park); 2009 Mar; 23(3):227-34. PubMed ID: 19418823
[TBL] [Abstract][Full Text] [Related]
25. Cardiotoxicity of Targeted Cancer Drugs: Concerns, "The Cart Before the Horse," and Lessons from Trastuzumab.
Menna P; Minotti G; Salvatorelli E
Curr Cardiol Rep; 2019 Mar; 21(5):33. PubMed ID: 30887161
[TBL] [Abstract][Full Text] [Related]
26. Modern Management of Anthracycline-Induced Cardiotoxicity in Lymphoma Patients: Low Occurrence of Cardiotoxicity with Comprehensive Assessment and Tailored Substitution by Nonpegylated Liposomal Doxorubicin.
Olivieri J; Perna GP; Bocci C; Montevecchi C; Olivieri A; Leoni P; Gini G
Oncologist; 2017 Apr; 22(4):422-431. PubMed ID: 28275118
[TBL] [Abstract][Full Text] [Related]
27. Cardiac Complications of Cancer Therapy: Pathophysiology, Identification, Prevention, Treatment, and Future Directions.
Jain D; Russell RR; Schwartz RG; Panjrath GS; Aronow W
Curr Cardiol Rep; 2017 May; 19(5):36. PubMed ID: 28374177
[TBL] [Abstract][Full Text] [Related]
28. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
29. Troponin as a cardiotoxicity marker in breast cancer patients receiving anthracycline-based chemotherapy: A narrative review.
Simões R; Silva LM; Cruz ALVM; Fraga VG; de Paula Sabino A; Gomes KB
Biomed Pharmacother; 2018 Nov; 107():989-996. PubMed ID: 30257411
[TBL] [Abstract][Full Text] [Related]
30. Characterization of subclinical diastolic dysfunction by cardiac magnetic resonance feature-tracking in adult survivors of non-Hodgkin lymphoma treated with anthracyclines.
Barbosa MF; Fusco DR; Gaiolla RD; Werys K; Tanni SE; Fernandes RA; Ribeiro SM; Szarf G
BMC Cardiovasc Disord; 2021 Apr; 21(1):170. PubMed ID: 33845778
[TBL] [Abstract][Full Text] [Related]
31. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
32. Chemotherapy-induced cardiotoxicity in children.
Bansal N; Amdani S; Lipshultz ER; Lipshultz SE
Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):817-832. PubMed ID: 28679288
[TBL] [Abstract][Full Text] [Related]
33. Are cardiac magnetic resonance imaging and radionuclide ventriculography good options against echocardiography for evaluation of anthracycline induced chronic cardiotoxicity in childhood cancer survivors?
Basar EZ; Corapcioglu F; Babaoglu K; Anik Y; Gorur Daglioz G; Dedeoglu R
Pediatr Hematol Oncol; 2014 Apr; 31(3):237-52. PubMed ID: 24499452
[TBL] [Abstract][Full Text] [Related]
34. Cardiotoxicity of Immune Checkpoint Inhibitors.
Zhang L; Jones-O'Connor M; Awadalla M; Zlotoff DA; Thavendiranathan P; Groarke JD; Villani AC; Lyon AR; Neilan TG
Curr Treat Options Cardiovasc Med; 2019 Jun; 21(7):32. PubMed ID: 31175469
[TBL] [Abstract][Full Text] [Related]
35. ICIs-Related Cardiotoxicity in Different Types of Cancer.
Dong M; Yu T; Zhang Z; Zhang J; Wang R; Tse G; Liu T; Zhong L
J Cardiovasc Dev Dis; 2022 Jun; 9(7):. PubMed ID: 35877565
[TBL] [Abstract][Full Text] [Related]
36. Will nanomedicine become a good solution for the cardiotoxicity of chemotherapy drugs?
Jiang Y; Jiang Y; Li M; Yu Q
Front Pharmacol; 2023; 14():1143361. PubMed ID: 37214453
[TBL] [Abstract][Full Text] [Related]
37. Cardiotoxicity and Cardiac Monitoring Among Chemotherapy-Treated Breast Cancer Patients.
Henry ML; Niu J; Zhang N; Giordano SH; Chavez-MacGregor M
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1084-1093. PubMed ID: 30092967
[TBL] [Abstract][Full Text] [Related]
38. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
39. Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis.
Chen X; Jiang A; Zhang R; Fu X; Liu N; Shi C; Wang J; Zheng X; Tian T; Liang X; Ruan Z; Yao Y
Front Cardiovasc Med; 2022; 9():882167. PubMed ID: 35669482
[TBL] [Abstract][Full Text] [Related]
40. Current status and future perspectives of onco-cardiology: Importance of early detection and intervention for cardiotoxicity, and cardiovascular complication of novel cancer treatment.
Kubota S; Hara H; Hiroi Y
Glob Health Med; 2021 Aug; 3(4):214-225. PubMed ID: 34532602
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]